Special Considerations, Incentives, and Programs To Support the Approval of New Animal Drugs for Minor Uses and for Minor Species; Guidance for Industry; Availability, 88634-88635 [2023-28287]
Download as PDF
88634
Federal Register / Vol. 88, No. 245 / Friday, December 22, 2023 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
regulatory submissions. In 2018, FDA
created an RWE Framework and
Program (Program) to evaluate the
potential use of RWE to help support
the approval of a new indication for a
drug already approved under the FD&C
Act or to help to support or satisfy
postapproval study requirements. In late
2021, FDA utilized the Program to issue
draft guidances outlining considerations
for the use of RWD and RWE in
regulatory decision-making to help
satisfy the Cures Act mandate and the
PDUFA VI commitment.
This guidance finalizes the draft
guidance entitled ‘‘Data Standards for
Drug and Biological Product
Submissions Containing Real-World
Data’’ issued on October 22, 2021 (86 FR
58672). FDA considered comments
received on the draft guidance as the
guidance was finalized. Changes from
the draft to the final guidance include
clarification of FDA’s understanding of
challenges when using currently
supported data standards for RWD
sources and elaboration of available
FDA resources for consultation about
the use of data standards for study data
submitted to FDA. In addition, editorial
changes were made to improve clarity,
including the movement of concepts
from glossary entries to footnotes to the
main document text.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on ‘‘Data Standards for
Drug and Biological Product
Submissions Containing Real-World
Data.’’ It does not establish any rights
for any person and is not binding on
FDA or the public. You can use an
alternative approach if it satisfies the
requirements of the applicable statutes
and regulations.
II. Paperwork Reduction Act of 1995
While this guidance contains no
collection of information, it does refer to
previously approved FDA collections of
information. The previously approved
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3521). The collections of information in
21 CFR part 314 (Applications for FDA
Approval to Market a New Drug) have
been approved under OMB control
number 0910–0001; the collections of
information in 21 CFR part 312
(Investigational New Drug Regulations)
have been approved under OMB control
number 0910–0014; the collections of
information in 21 CFR part 58 (Good
Laboratory Practice Regulations for
Nonclinical Laboratory Studies) have
VerDate Sep<11>2014
18:10 Dec 21, 2023
Jkt 262001
been approved under OMB control
number 0910–0119; and the collections
of information in 21 CFR part 601
(General Licensing Provisions: Biologics
License Application, Changes to an
Approved Application, Labeling,
Revocation and Suspension) have been
approved under OMB control number
0910–0338.
III. Electronic Access
Persons with access to the internet
may obtain the guidance at https://
www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs, https://www.fda.gov/
regulatory-information/search-fdaguidance-documents, or https://
www.regulations.gov.
Dated: December 19, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–28291 Filed 12–21–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
[Docket No. FDA–1997–D–0444]
Written/Paper Submissions
Special Considerations, Incentives,
and Programs To Support the
Approval of New Animal Drugs for
Minor Uses and for Minor Species;
Guidance for Industry; Availability
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
1997–D–0444 for ‘‘Special
Considerations, Incentives, and
Programs to Support the Approval of
New Animal Drugs for Minor Uses and
for Minor Species.’’ Received comments
will be placed in the docket and, except
for those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA, the Agency, or
we) is announcing the availability of a
final guidance for industry (GFI) #61
entitled ‘‘Special Considerations,
Incentives, and Programs to Support the
Approval of New Animal Drugs for
Minor Uses and for Minor Species.’’
This guidance is intended to assist those
interested in pursuing FDA approval of
new animal drugs intended for minor
uses in major species or for use in minor
species (MUMS drugs). It outlines the
basic statutory and regulatory
requirements and special considerations
for these approvals and describes the
incentives available to encourage the
development of MUMS drugs.
DATES: The announcement of the
guidance is published in the Federal
Register on December 22, 2023.
ADDRESSES: You may submit either
electronic or written comments on
Agency guidances at any time as
follows:
SUMMARY:
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
E:\FR\FM\22DEN1.SGM
22DEN1
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 245 / Friday, December 22, 2023 / Notices
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)). Submit written requests
for single copies of the guidance to the
Policy and Regulations Staff (HFV–6),
Center for Veterinary Medicine, Food
and Drug Administration, 7500 Standish
Pl., Rockville, MD 20855. Send one selfaddressed adhesive label to assist that
office in processing your requests. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT:
Dorothy Bailey, Center for Veterinary
Medicine (HFV–50), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–402–0565,
dorothy.bailey@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of July 15,
2020 (85 FR 42876), FDA published the
notice of availability for draft GFI #61
entitled ‘‘Special Considerations,
Incentives, and Programs to Support the
Approval of New Animal Drugs for
VerDate Sep<11>2014
18:10 Dec 21, 2023
Jkt 262001
Minor Uses and for Minor Species’’
giving interested persons until
November 12, 2020, to comment on the
draft guidance. In response to a request
for an extension, the comment period
was extended to January 11, 2021 (85 FR
71659). FDA received 14 comments on
the draft guidance and those comments
were considered as the guidance was
finalized. Changes to the final guidance
include the following:
• In our draft guidance we referred to
Minor Use Determinations. Our
experience has shown that our
stakeholders frequently confuse
‘‘MUMS Determination’’ with ‘‘MUMS
Designation.’’ Therefore, the final
guidance substitutes the word
‘‘Assessment’’ for the word
‘‘Determination.’’
• Section XII.C.3.a.i. ‘‘Anthelmintics
and Ectoparasiticides for Terrestrial
Minor Species’’ has been added to the
final guidance in response to comments
received requesting additional detail on
this subject. This section also references
the relevant ‘‘International Cooperation
on Harmonisation of Technical
Requirements for Registration of
Veterinary Medicinal Products (VICH)’’
guidance.
• CVM received many comments
pertaining to aquaculture species
grouping. Due to the complexity of this
topic, CVM has removed examples of
aquaculture species groupings in the
final guidance. We continue to consider
this topic and intend to work with
individual drug sponsors wishing to use
species groupings for new animal drug
approvals to identify an appropriate
species grouping strategy and
subsequent data needs for specific
projects.
In addition, editorial changes were
made to improve clarity. The guidance
announced in this notice finalizes the
draft guidance dated July 2020.
This level 1 guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on ‘‘Special
Considerations, Incentives, and
Programs to Support the Approval of
New Animal Drugs for Minor Uses and
for Minor Species.’’ It does not establish
any rights for any person and is not
binding on FDA or the public. You can
use an alternative approach if it satisfies
the requirements of the applicable
statutes and regulations.
II. Paperwork Reduction Act of 1995
While this guidance contains no
collection of information, it does refer to
previously approved FDA collections of
information. The previously approved
collections of information are subject to
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
88635
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (PRA) (44 U.S.C.
3501–3521). The collections of
information in 21 CFR part 511 have
been approved under OMB control
number 0910–0117; the collections of
information in 21 CFR part 514 have
been approved under OMB control
numbers 0910–0032 and 0910–0284;
and the collections of information in 21
CFR part 516 have been approved under
OMB control numbers 0910–0605.
III. Electronic Access
Persons with access to the internet
may obtain the guidance at https://
www.fda.gov/animal-veterinary/
guidance-regulations/guidanceindustry, https://www.fda.gov/
regulatory-information/search-fdaguidance-documents, or https://
www.regulations.gov.
Dated: December 19, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–28287 Filed 12–21–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA–2023–N–1157; FDA–
2022–D–0109; FDA–2020–N–0908; FDA–
2022–D–0814; FDA–2022–D–0745; FDA–
2023–N–1006; FDA–2023–N–1053; FDA–
2023–N–2286; FDA–2023–N–1661; FDA–
2013–N–1119; FDA–2023–N–2986; FDA–
2009–N–0582; FDA–2023–N–1272; FDA–
2023–N–2030; FDA–2023–N–1189]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approvals
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is publishing a
list of information collections that have
been approved by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
JonnaLynn Capezzuto, Office of
Operations, Food and Drug
Administration, Three White Flint
North, 10A–12M, 11601 Landsdown St.,
North Bethesda, MD 20852, 301–796–
3794, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: The
following is a list of FDA information
collections recently approved by OMB
under section 3507 of the Paperwork
Reduction Act of 1995 (44 U.S.C. 3507).
SUMMARY:
E:\FR\FM\22DEN1.SGM
22DEN1
Agencies
[Federal Register Volume 88, Number 245 (Friday, December 22, 2023)]
[Notices]
[Pages 88634-88635]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-28287]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-1997-D-0444]
Special Considerations, Incentives, and Programs To Support the
Approval of New Animal Drugs for Minor Uses and for Minor Species;
Guidance for Industry; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is
announcing the availability of a final guidance for industry (GFI) #61
entitled ``Special Considerations, Incentives, and Programs to Support
the Approval of New Animal Drugs for Minor Uses and for Minor
Species.'' This guidance is intended to assist those interested in
pursuing FDA approval of new animal drugs intended for minor uses in
major species or for use in minor species (MUMS drugs). It outlines the
basic statutory and regulatory requirements and special considerations
for these approvals and describes the incentives available to encourage
the development of MUMS drugs.
DATES: The announcement of the guidance is published in the Federal
Register on December 22, 2023.
ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-1997-D-0444 for ``Special Considerations, Incentives, and Programs
to Support the Approval of New Animal Drugs for Minor Uses and for
Minor Species.'' Received comments will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at https://www.regulations.gov or at the Dockets Management
Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the
[[Page 88635]]
information you claim to be confidential with a heading or cover note
that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The
Agency will review this copy, including the claimed confidential
information, in its consideration of comments. The second copy, which
will have the claimed confidential information redacted/blacked out,
will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management
Staff. If you do not wish your name and contact information to be made
publicly available, you can provide this information on the cover sheet
and not in the body of your comments and you must identify this
information as ``confidential.'' Any information marked as
``confidential'' will not be disclosed except in accordance with 21 CFR
10.20 and other applicable disclosure law. For more information about
FDA's posting of comments to public dockets, see 80 FR 56469, September
18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)). Submit written requests for single copies of the
guidance to the Policy and Regulations Staff (HFV-6), Center for
Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl.,
Rockville, MD 20855. Send one self-addressed adhesive label to assist
that office in processing your requests. See the SUPPLEMENTARY
INFORMATION section for electronic access to the guidance document.
FOR FURTHER INFORMATION CONTACT: Dorothy Bailey, Center for Veterinary
Medicine (HFV-50), Food and Drug Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240-402-0565, [email protected].
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of July 15, 2020 (85 FR 42876), FDA
published the notice of availability for draft GFI #61 entitled
``Special Considerations, Incentives, and Programs to Support the
Approval of New Animal Drugs for Minor Uses and for Minor Species''
giving interested persons until November 12, 2020, to comment on the
draft guidance. In response to a request for an extension, the comment
period was extended to January 11, 2021 (85 FR 71659). FDA received 14
comments on the draft guidance and those comments were considered as
the guidance was finalized. Changes to the final guidance include the
following:
In our draft guidance we referred to Minor Use
Determinations. Our experience has shown that our stakeholders
frequently confuse ``MUMS Determination'' with ``MUMS Designation.''
Therefore, the final guidance substitutes the word ``Assessment'' for
the word ``Determination.''
Section XII.C.3.a.i. ``Anthelmintics and Ectoparasiticides
for Terrestrial Minor Species'' has been added to the final guidance in
response to comments received requesting additional detail on this
subject. This section also references the relevant ``International
Cooperation on Harmonisation of Technical Requirements for Registration
of Veterinary Medicinal Products (VICH)'' guidance.
CVM received many comments pertaining to aquaculture
species grouping. Due to the complexity of this topic, CVM has removed
examples of aquaculture species groupings in the final guidance. We
continue to consider this topic and intend to work with individual drug
sponsors wishing to use species groupings for new animal drug approvals
to identify an appropriate species grouping strategy and subsequent
data needs for specific projects.
In addition, editorial changes were made to improve clarity. The
guidance announced in this notice finalizes the draft guidance dated
July 2020.
This level 1 guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The guidance represents
the current thinking of FDA on ``Special Considerations, Incentives,
and Programs to Support the Approval of New Animal Drugs for Minor Uses
and for Minor Species.'' It does not establish any rights for any
person and is not binding on FDA or the public. You can use an
alternative approach if it satisfies the requirements of the applicable
statutes and regulations.
II. Paperwork Reduction Act of 1995
While this guidance contains no collection of information, it does
refer to previously approved FDA collections of information. The
previously approved collections of information are subject to review by
the Office of Management and Budget (OMB) under the Paperwork Reduction
Act of 1995 (PRA) (44 U.S.C. 3501-3521). The collections of information
in 21 CFR part 511 have been approved under OMB control number 0910-
0117; the collections of information in 21 CFR part 514 have been
approved under OMB control numbers 0910-0032 and 0910-0284; and the
collections of information in 21 CFR part 516 have been approved under
OMB control numbers 0910-0605.
III. Electronic Access
Persons with access to the internet may obtain the guidance at
https://www.fda.gov/animal-veterinary/guidance-regulations/guidance-industry, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.regulations.gov.
Dated: December 19, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-28287 Filed 12-21-23; 8:45 am]
BILLING CODE 4164-01-P